Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial

CONCLUSIONS AND RELEVANCE: The findings of this nonrandomized clinical trial suggest that camrelizumab plus apatinib and temozolomide may be a potential first-line treatment option for patients with advanced acral melanoma, which warrants further validation in a randomized clinical trial.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04397770.PMID:37261804 | DOI:10.1001/jamaoncol.2023.1363

Source: Cancer Control - June 1, 2023 Category: Cancer & Oncology Authors: Lili Mao Bin Lian Caili Li Xue Bai Li Zhou Chuanliang Cui Zhihong Chi Xinan Sheng Xuan Wang Bixia Tang Xieqiao Yan Siming Li Yan Kong Jie Dai Xiaoting Wei Juan Li Rong Duan Huayan Xu Xiaowen Wu Yue Yang Fengzhuo Cheng Cheng Zhang Fangzhou Xia Zheng Pang J Source Type: research